AnaptysBio Analyst Price Targets

Wall Street analyst price targets and consensus rating for AnaptysBio (ANAB).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

12Buy

2Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$70Upside to Avg. PT+40.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$70→$60
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$95
Sep 23, 2026	Leerink Partners	David Risinger	PT Cut	Outperform	$90→$81
Aug 25, 2026	TD Cowen	Joseph Thome	PT Cut	Buy	$75→$70
Aug 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$95
Jun 10, 2026	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$95
May 13, 2026	UBS	Michael Yee	PT Raise	Buy	$60→$76
May 13, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$63→$75
May 4, 2026	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$95→$93
Apr 28, 2026	Leerink Partners	David Risinger	PT Raise	Outperform	$66→$85
Apr 22, 2026	Barclays	Etzer Darout	PT Cut	Overweight	$79→$63
Apr 21, 2026	UBS	Michael Yee	PT Cut	Buy	$90→$60
Mar 31, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$67→$95
Mar 30, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$66
Mar 17, 2026	UBS	Michael Yee	PT Raise	Buy	$70→$90
Mar 12, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$60→$75
Mar 9, 2026	Truist Securities	John Lee	PT Raise	Hold	$36→$50
Mar 5, 2026	Stifel	Alex Thompson	PT Raise	Buy	$56→$85
Mar 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$78→$79
Mar 4, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$51→$66

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $95.

Benzinga Newsdesk

AnaptysBio Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AnaptysBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

People Also Watch

People Also Watch

AnaptysBio Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AnaptysBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PROHC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PROLeerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PROTD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PROHC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PROHC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95